Headlines about Apricus Biosciences (NASDAQ:APRI) have been trending positive this week, according to Accern Sentiment. The research group identifies positive and negative press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Apricus Biosciences earned a news impact score of 0.28 on Accern’s scale. Accern also gave headlines about the company an impact score of 46.3584666519113 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
APRI has been the topic of a number of recent research reports. HC Wainwright set a $5.00 target price on Apricus Biosciences and gave the company a “buy” rating in a research note on Tuesday, January 16th. ValuEngine upgraded Apricus Biosciences from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd. Finally, Zacks Investment Research downgraded Apricus Biosciences from a “hold” rating to a “sell” rating in a research note on Thursday, February 22nd.
Shares of Apricus Biosciences (NASDAQ:APRI) traded down $0.03 during midday trading on Thursday, reaching $0.72. The company’s stock had a trading volume of 322,144 shares, compared to its average volume of 1,930,000. Apricus Biosciences has a 1 year low of $0.63 and a 1 year high of $3.34. The stock has a market capitalization of $11.01, a P/E ratio of -0.68 and a beta of 0.96.
WARNING: This news story was posted by Week Herald and is the property of of Week Herald. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The original version of this news story can be read at https://weekherald.com/2018/03/15/apricus-biosciences-apri-receives-media-impact-rating-of-0-28.html.
About Apricus Biosciences
Apricus Biosciences, Inc is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company’s drug delivery technology is a permeation enhancer called NexACT.
Receive News & Ratings for Apricus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apricus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.